R C Hoogeveen1, C M Ballantyne, H Bang, G Heiss, B B Duncan, A R Folsom, J S Pankow. 1. Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA. ronh@bcm.tmc.edu
Abstract
AIMS/HYPOTHESIS: To evaluate the role of oxidative stress and inflammation in the aetiology of type 2 diabetes, we examined the association of oxidised LDL (ox-LDL) and soluble intercellular adhesion molecule-1 (sICAM-1) levels with type 2 diabetes incidence over 9 years in the Atherosclerosis Risk in Communities Study. MATERIALS AND METHODS: In a large, prospective, case-cohort design, ox-LDL and sICAM-1 were measured in stored plasma samples collected at baseline in stratified samples of 581 diabetes cases and 572 non-cases selected from 10,275 middle-aged men and women without prevalent diabetes at baseline. RESULTS: Compared with non-cases, diabetes cases had significantly higher mean baseline levels of ox-LDL and sICAM-1. Elevated ox-LDL and sICAM-1 were both associated with increased risk of incident diabetes after adjustment for age, sex, race and centre, with hazard ratios for the highest vs lowest tertiles of 1.68 (95% CI 1.25-2.24) and 1.91 (95% CI 1.45-2.50), respectively. After additional adjustment for fasting glucose, waist circumference, HDL-cholesterol, triacylglycerol, hypertension and C-reactive protein, only sICAM-1 remained an independent predictor of incident diabetes (hazard ratio 1.50; 95% CI 1.02-2.23). CONCLUSIONS/ INTERPRETATION: In this community-based cohort of middle-aged US adults, elevated plasma ox-LDL and sICAM-1 levels were associated with increased risk of type 2 diabetes. Measurement of ICAM-1 or ox-LDL, or other measures related to inflammation or oxidative stress, may be helpful in identifying those patient populations in which to test whether novel therapies that inhibit specific pathways related to inflammation or oxidative stress are beneficial in the prevention of diabetes in humans.
AIMS/HYPOTHESIS: To evaluate the role of oxidative stress and inflammation in the aetiology of type 2 diabetes, we examined the association of oxidised LDL (ox-LDL) and soluble intercellular adhesion molecule-1 (sICAM-1) levels with type 2 diabetes incidence over 9 years in the Atherosclerosis Risk in Communities Study. MATERIALS AND METHODS: In a large, prospective, case-cohort design, ox-LDL and sICAM-1 were measured in stored plasma samples collected at baseline in stratified samples of 581 diabetes cases and 572 non-cases selected from 10,275 middle-aged men and women without prevalent diabetes at baseline. RESULTS: Compared with non-cases, diabetes cases had significantly higher mean baseline levels of ox-LDL and sICAM-1. Elevated ox-LDL and sICAM-1 were both associated with increased risk of incident diabetes after adjustment for age, sex, race and centre, with hazard ratios for the highest vs lowest tertiles of 1.68 (95% CI 1.25-2.24) and 1.91 (95% CI 1.45-2.50), respectively. After additional adjustment for fasting glucose, waist circumference, HDL-cholesterol, triacylglycerol, hypertension and C-reactive protein, only sICAM-1 remained an independent predictor of incident diabetes (hazard ratio 1.50; 95% CI 1.02-2.23). CONCLUSIONS/ INTERPRETATION: In this community-based cohort of middle-aged US adults, elevated plasma ox-LDL and sICAM-1 levels were associated with increased risk of type 2 diabetes. Measurement of ICAM-1 or ox-LDL, or other measures related to inflammation or oxidative stress, may be helpful in identifying those patient populations in which to test whether novel therapies that inhibit specific pathways related to inflammation or oxidative stress are beneficial in the prevention of diabetes in humans.
Authors: S Toshima; A Hasegawa; M Kurabayashi; H Itabe; T Takano; J Sugano; K Shimamura; J Kimura; I Michishita; T Suzuki; R Nagai Journal: Arterioscler Thromb Vasc Biol Date: 2000-10 Impact factor: 8.311
Authors: M I Schmidt; B B Duncan; A R Sharrett; G Lindberg; P J Savage; S Offenbacher; M I Azambuja; R P Tracy; G Heiss Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: K Nakai; C Itoh; K Kawazoe; Y Miura; H Sotoyanagi; K Hotta; T Itoh; J Kamata; K Hiramori Journal: Coron Artery Dis Date: 1995-06 Impact factor: 1.439
Authors: C M Ballantyne; E A Mainolfi; J B Young; N T Windsor; B Cocanougher; E C Lawrence; M S Pollack; M L Entman; R Rothlein Journal: J Heart Lung Transplant Date: 1994 Jul-Aug Impact factor: 10.247
Authors: Paul Holvoet; Stephen B Kritchevsky; Russell P Tracy; Ann Mertens; Susan M Rubin; Javed Butler; Bret Goodpaster; Tamara B Harris Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Anne L Norris; Julia Steinberger; Lyn M Steffen; Andrea M Metzig; Sarah Jane Schwarzenberg; Aaron S Kelly Journal: Obesity (Silver Spring) Date: 2011-02-17 Impact factor: 5.002
Authors: Omer T Njajou; Alka M Kanaya; Paul Holvoet; Stephanie Connelly; Elsa S Strotmeyer; Tamara B Harris; Steve R Cummings; Wen-Chi Hsueh Journal: Diabetes Metab Res Rev Date: 2009-11 Impact factor: 4.876
Authors: J S Pankow; P A Decker; C Berardi; N Q Hanson; M Sale; W Tang; A M Kanaya; N B Larson; M Y Tsai; C L Wassel; S J Bielinski Journal: Diabet Med Date: 2016-03-25 Impact factor: 4.359
Authors: Vivian C Luft; Maria I Schmidt; James S Pankow; David Couper; Christie M Ballantyne; J Hunter Young; Bruce B Duncan Journal: Diabetol Metab Syndr Date: 2013-06-27 Impact factor: 3.320
Authors: L A Raynor; James S Pankow; Bruce B Duncan; Maria I Schmidt; Ron C Hoogeveen; Mark A Pereira; J Hunter Young; Christie M Ballantyne Journal: Diabetes Care Date: 2012-08-28 Impact factor: 19.112
Authors: Andrzej Surdacki; Olga Kruszelnicka; Tomasz Rakowski; Aleksandra Jaźwińska-Kozuba; Jacek S Dubiel Journal: Cardiovasc Diabetol Date: 2013 Impact factor: 9.951